The Quantellect read.As of Nov 20, 2026, 15 active firms cover Hinge Health, Inc: 14 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $59.00 to $140.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $100.93 sits 7% below the current $108.18. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.64 next quarter toward $3.26 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS15 active firms
Buy
Strong Buy00%
Buy1493%
Neutral17%
Sell00%
Strong Sell00%
Based on 15 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$100.93
-6.7% downside
Average target across 15 active firms as of Nov 20, 2026 vs $108.18 current
Highest Target$140.00
Average Target$100.93
Lowest Target$59.00
Detailed analyst forecasts for HNGE
Showing 1–15 of 15 named analysts shown · 15 active firms in the rating projection
As of Nov 20, 2026, 14 of 15 active firms rate HNGE a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
HNGE EPS & revenue forecast
EPS · NEXT QUARTER
$0.64
Range $0.54 – $0.72 · 12 analysts · +43% YoY
Next period, 12 analysts expect Hinge Health, Inc. to earn $0.64 a share (range $0.54 – $0.72), versus $0.45 a year earlier. Full-year consensus is $2.57, growing to $3.26 the year after.
REVENUE · NEXT QUARTER
$248.6M
Range $232.8M – $255.0M · 12 analysts · +36% YoY
Revenue is expected to reach $248.6M (range $232.8M – $255.0M), +36.3% year-over-year. Full-year consensus is $878.0M, rising to $1.1B next year.
Top analysts covering Hinge Health, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HNGE.
#1
Richard Close
Canaccord Genuity · Rank #249
Buy
$105.00-2.9% to target
Overall win rate
37%
+ Follow
#2
Rishi Jaluria
RBC Capital · Rank #389
Buy
$135.00+24.8% to target
Overall win rate
36%
+ Follow
#3
Brian Peterson
Raymond James · Rank #539
Buy
$138.00+27.6% to target
Overall win rate
24%
+ Follow
#4
Scott Schoenhaus
Keybanc · Rank #540
Buy
$140.00+29.4% to target
Overall win rate
30%
+ Follow
#5
Ryan MacDonald
Needham · Rank #579
Buy
$115.00+6.3% to target
Overall win rate
19%
+ Follow
HNGE stock forecast FAQ
What is HNGE's average 12-month price target?+
The 15 active firms with a live target average $100.93 for Hinge Health, Inc. over the next 12 months, ranging from a $140.00 high to a $59.00 low, as of Nov 20, 2026.
Is HNGE stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 15 active firms as of Nov 20, 2026, 14 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for HNGE?+
The Street-high target is $140.00 (Keybanc), and the Street-low is $59.00 (Freedom Capital Markets). The average of all 15 active-firm targets is $100.93.
How many active Wall Street firms cover HNGE?+
15 active firms have a recognized rating on Hinge Health, Inc. as of Nov 20, 2026, and 15 active firms carry a live 12-month price target.
Who is the most accurate analyst covering HNGE?+
Among analysts who currently cover HNGE, Richard Close of Canaccord Genuity has the strongest overall Quantellect track record (Rank #249). Their current call is Buy with a $105.00 target.
What is Hinge Health, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.64 per share (range $0.54 – $0.72) across 12 analysts. Full-year EPS is projected at $2.57, rising to $3.26 the following year.
How much revenue is Hinge Health, Inc. expected to report next quarter?+
Consensus revenue is $248.6M (range $232.8M – $255.0M). Full-year revenue is projected at $878.0M, growing to $1.1B next year.
Have analysts been upgrading or downgrading HNGE lately?+
As of Nov 20, 2026, 14 of 15 active firms rate HNGE a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HNGE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.